Suchergebnisse - "Remission Induction"

PubPharm (354)

11

Clinical Evaluation of Risankizumab in the Treatment of Adults with Moderately to Severely Active Crohn's Disease : Patient Selection and Reported Outcomes

enthalten in: Drug design, development and therapy | 2023

von Horst, S. | Cross, R.

12

Clinical Evaluation of Risankizumab in the Treatment of Adults with Moderately to Severely Active Crohn’s Disease: Patient Selection and Reported Outcomes

in: Drug Design, Development and Therapy | 2023

von Horst S | Cross RK

13

Acute Heart Failure Is a Malignant Process: But We Can Induce Remission

in: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease | 2023

von Gad Cotter | Beth A. Davison | Carolyn S. P. Lam | +4

14

Assessment of soluble syndecan-1 level in adult patients with de novo acute myeloid leukemia and its correlation with hematological parameters and treatment response

in: Iraqi Journal of Hematology | 2023

von Riyam Ismael Shaker | Israa M Al-Bayaa

15

Evaluation of Proactive Therapeutic Drug Monitoring Application in Infliximab Users in Ulcerative Colitis

in: Journal of Coloproctology | 2023

von Gabriela Maria Henz Giovelli | Ornella Sari Cassol | Marcio Lubini | +3

16

Phase II/III Study for Remission Induction With Bortezomib (Vel), Cyclophosphamide (C) and Dexamethasone (D) in Patients <= 60 Years With Untreated Multiple Myeloma and Planned High Dose Chemotherapy: (VelCD) : Phase II/III Study for Remission Induction With Bortezomib (Vel), Cyclophosphamide (C) and Dexamethasone (D) in Patients <= 60 Years With Untreated Multiple Myeloma and Planned High Dose Chemotherapy: (VelCD)

enthalten in: WHO International Clinical Trials Registry Platform | 2022

17

Phase II/III Study for Remission Induction With Bortezomib (Vel), Cyclophosphamide (C) and Dexamethasone (D) in Patients <= 60 Years With Untreated Multiple Myeloma and Planned High Dose Chemotherapy: (VelCD) : Phase II/III Study for Remission Induction With Bortezomib (Vel), Cyclophosphamide (C) and Dexamethasone (D) in Patients <= 60 Years With Untreated Multiple Myeloma and Planned High Dose Chemotherapy: (VelCD)

enthalten in: WHO International Clinical Trials Registry Platform | 2022

18

Psychometric evaluation of the Urgency NRS as a new patient-reported outcome measure for patients with ulcerative colitis

enthalten in: Journal of patient-reported outcomes | 2022

von Dubinsky, M. | Shan, M. | Delbecque, L. | +6

19

Psychometric evaluation of the Urgency NRS as a new patient-reported outcome measure for patients with ulcerative colitis

enthalten in: Journal of patient-reported outcomes | 2022

von Dubinsky, M. | Shan, M. | Delbecque, L. | +6

20

Psychometric evaluation of the Urgency NRS as a new patient-reported outcome measure for patients with ulcerative colitis

enthalten in: Journal of patient-reported outcomes | 2022

von Dubinsky, M. | Shan, M. | Delbecque, L. | +6